Determination of Disk Diffusion and MIC Quality Control Guidelines for GSK2140944, a Novel Bacterial Type II Topoisomerase Inhibitor Antimicrobial Agent

James E. Ross; Nicole E. Scangarella-Oman; Robert K. Flamm; Ronald N. Jones

首页> 外文期刊>Journal of Clinical Microbiology >Determination of Disk Diffusion and MIC Quality Control Guidelines for GSK2140944, a Novel Bacterial Type II Topoisomerase Inhibitor Antimicrobial Agent

【24h】

Determination of Disk Diffusion and MIC Quality Control Guidelines for GSK2140944, a Novel Bacterial Type II Topoisomerase Inhibitor Antimicrobial Agent

机译：磁盘扩散的确定以及MIC II细菌拓扑异构酶抑制剂抗菌剂GSK2140944的MIC质量控制指南

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

GSK2140944 is a novel bacterial type II topoisomerase inhibitor in development for the treatment of conventional and biothreat pathogens, including Gram-positive pathogens and methicillin-resistant Staphylococcus aureus. This quality control study was performed to establish ranges for selected control strains: S. aureus ATCC 29213 and ATCC 25923, Escherichia coli ATCC 25922, Haemophilus influenzae ATCC 49247, and Streptococcus pneumoniae ATCC 49619. The control ranges will be crucial for the accurate evaluation of GSK2140944 potency as it progresses through clinical trial development.

机译：GSK2140944是正在开发的新型细菌II型拓扑异构酶抑制剂，用于治疗常规和生物威胁性病原体，包括革兰氏阳性病原体和耐甲氧西林的金黄色葡萄球菌。进行了这项质量控制研究，以建立选定对照菌株的范围：金黄色葡萄球菌ATCC 29213和ATCC 25923，大肠杆菌ATCC 25922，流感嗜血杆菌ATCC 49247和肺炎链球菌ATCC49619。控制范围对于准确评估A.随着临床试验的发展，GSK2140944的功效。

著录项

来源
《Journal of Clinical Microbiology》 |2014年第7期|共4页
作者
James E. Ross; Nicole E. Scangarella-Oman; Robert K. Flamm; Ronald N. Jones;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类医学微生物学（病原细菌学、病原微生物学）;
关键词

相似文献

外文文献
中文文献
专利

1. NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy (Antimicrobial Agents and Chemotherapy (2014) 58, 5, (2657-2664)) [J] . DoughertyT.J., NayarA., NewmanJ.V., Antimicrobial agents and chemotherapy. . 2014,第7期

机译：NBTI 5463是一种新型细菌II型拓扑异构酶抑制剂，具有抗革兰氏阴性细菌的活性和体内功效（Antimicrobial Agents and Chemotherapy（2014）58，5，（2657-2664））
2. Antimicrobial activity of SCH27899 (Ziracin), a novel everninomicin derivative, tested against Streptococcus spp.: disk diffusion/etest method evaluations and quality control guidelines. The Quality Control Study Group. [J] . Marshall SA, Jones RN, Erwin ME Diagnostic microbiology and infectious disease . 1999,第1期

机译：SCH27899（Ziracin）（一种新型的everninomicin衍生物）的抗菌活性针对链球菌进行了测试：纸片扩散/测试方法评估和质量控制指南。质量控制研究小组。
3. Determination of MIC and disk diffusion quality control guidelines for meropenem-vaborbactam, a novel carbapenem/boronic acid beta-lactamase inhibitor combination [J] . Munson Erik, Huband Michael D., Castanheira Mariana, Diagnostic microbiology and infectious disease . 2018,第4期

机译：MIC和磁盘扩散质量控制指南的测定，新型肉豆蔻/硼酸β-内酰胺酶抑制剂组合
4. Continuous using of antimicrobial agents less than 6 months or using non-fluoroquinolone antimicrobial agents reduced the occurrence of spontaneous bacterial peritonitis and improved the survival rates in cirrhosis: A meta-analysis [C] . Li-hui Long, Ya-ting Lv, Li Xu, International Conference on Biological Information and Biomedical Engineering . 2018

机译：连续使用少于6个月或使用非氟喹诺酮抗微生物剂的抗菌药物减少了自发性细菌性腹膜炎的发生，并改善了肝硬化的存活率：Meta分析
5. Understanding Substrate Selection and Functional Output of Bacterial Type IIA Topoisomerase Orthologs and Paralogs [D] . Tretter, Elsa Marie 2012

机译：了解细菌IIA型拓扑异构酶直向同源物和旁系同源物的底物选择和功能输出
6. Determination of Disk Diffusion and MIC Quality Control Guidelines for GSK2140944 a Novel Bacterial Type II Topoisomerase Inhibitor Antimicrobial Agent [O] . James E. Ross, Nicole E. Scangarella-Oman, Robert K. Flamm, 2014

机译：磁盘扩散测定和MIC细菌II型拓扑异构酶抑制剂抗菌剂GSK2140944的MIC质量控制指南
7. Determination of Disk Diffusion and MIC Quality Control Guidelines for GSK2140944, a Novel Bacterial Type II Topoisomerase Inhibitor Antimicrobial Agent [O] . J. E. Ross, N. E. Scangarella-Oman, R. K. Flamm, 2014

机译：GSK2140944的磁盘扩散和MIC质量控制指南，一种新型细菌II型拓扑异构酶抑制剂抗微生物剂

Determination of Disk Diffusion and MIC Quality Control Guidelines for GSK2140944, a Novel Bacterial Type II Topoisomerase Inhibitor Antimicrobial Agent

摘要

著录项

相似文献

相关主题

期刊订阅